anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Novel methods of treating tumors, including neuroendocrine tumors (NET), such as a catecholamine-secreting tumor (CST), are disclosed. The methods include treating Cushing&#39;s syndrome in a Cushing&#39;s syndrome patient having a NET, such as a CST. Tumors may be treated with a glucocorticoid receptor (GR) modulator (GRM), such as a GR antagonist (GRA). The novel treatments may treat Cushing&#39;s syndrome, may reduce catecholamine production by the tumor, may reduce catecholamine excess, may ameliorate symptoms of catecholamine excess, and may improve the efficacy of α- or β-adrenergic blockade, somatostatin or somatostatin analog treatment or imaging, or Peptide Receptor Radionuclide Therapy, in patients with a CST. The GRM may reduce the activation of a GR, and may bind to a GR with higher affinity than it binds to a progesterone receptor (PR). In embodiments, the drug may only poorly bind to PR, or may not measurably bind to PR.
The invention provides, in some aspects, a container system for medical solutions such as peritoneal dialysis (PD) solutions. The invention particularly features a system which includes a first compartment that contains a first medical solution, e.g., a PD osmotic agent, and a second compartment that contains a second medical solution, e.g., a PD buffer agent. The compartments maintain their respective contents separately from one another for purposes of transport, storage and/or sterilization. However, the compartments are fluidly couplable, so that their respective contents can be combined with one another, e.g., following sterilization of the agents and prior to their introduction into the patient&#39;s abdomen. To that end, a container system can include a diffuser that is disposed in a fluid pathway between the first and second compartments, e.g., to facilitate homogeneous mixing of the first and second PD agents. That diffuser is disposed within and moves relative to a structure, such as a port that defines the fluid pathway between those compartment. Thus, for example, the diffuser can comprise a body that “floats” within that pathway-defining structure and that moves from one end to the other (and/or to from points there between), depending on a direction of solution flow through the structure.
The invention is directed to &#34;determining the occurrence of focal and/or trochanteric arrhythmogenic activity in a region of cardiac tissue&#34;. The invention provides a method, comprising the following steps: in a processor, a two-dimensional (2D) electro-anatomical (EA) map of an inner surface of at least a portion of a cavity of an organ of a patient is received, the 2D EA map including Electrophysiological (EP) values measured at respective locations on the inner surface. A complex analytic function is fitted to the set of EP values measured in a given region of the 2D EA map. Singularities in the fitted complex analytic function are identified. The region is projected onto a three-dimensional (3D) EA map of the interior surface. Presenting at least a portion of the 3D EA map to a user, including indicating arrhythmogenic EP activity at locations on the 3D EA map that correspond to the singularities identified in the fitted complex analytic function.
FIELD: veterinary science. SUBSTANCE: in combination with dietotherapy and vitaminotherapy animals were given orally tetracycline and nistatin for 10-12 days and after interval for 4-5 days - trichopol for 10-12 days at the known doses. Simultaneously, damaged skin regions were treated with actinolyzate for 4-5 days (in the morning and evening), then - three-fold (interval for 4-5 days) with 5% oily solution of ASD-3 (once per a day). Simultaneously, physiotherapy procedures were carried out followed by mycoseptin rubbing in the skin; after 5-6 days this treatment schedule is repeated; after the second course of physiotherapy preparation containing sea buckthorn is used, for example, aerosol olasol. Sick animals receive 10-12 physiotherapy procedures for 10-15 min involving the simultaneous use of ultraviolet, infrared irradiation and local d&#39;Arsonval treatment. EFFECT: improved method of treatment, enhanced effectiveness. 3 cl, 1 tbl
1,160,640. Anti-caries compositions. PROCTER &amp; GAMBLE CO. 29 Dec., 1967 [29 Dec., 1966], No. 59117/67. Heading A5B. [Also in Division C2] An oral composition for caries prophylaxis comprises:-(a) at least one water-soluble fluoride in a quantity sufficient to provide from 25 to 4000‹ parts of fluoride ions per million parts by weight of the composition, and (b) from 0.05% to 5.0% by weight of at least one distannous salt of a gem-diphosphonic acid having the formula:- wherein R 1  is hydrogen, halogen, hydroxyl, benzyl, alkyl, hydroxyalkyl, methoxyalkyl or carboxyalkyl and has up to 12 carbon atoms and R 2  is hydrogen, halogen, hydroxyl, acetyl, phenyl, benzyl, alkyl, hydroxyalkyl, methoxyalkyl or carboxyalkyl and has up to 12 carbon atoms. Many distannous diphosphonates are specified, distannous methanoediphosphonate and distannous ethane-1-hydroxy-1,1-diphosphonate being preferred. The water-soluble fluoride may be an inorganic fluoride, an amine hydrofluoride, a hydroxyalkyl alkyl anarnonium fluoride of specified type or an addition compound of an amino acid and an hydrofluoric acid or a fluoride. The preferred fluoride is stannous fluoride used in a quantity sufficient to provide a total amount of at least 300 parts per million of stannous tin. The pH of the compositions is suitably between 2.5 and 7. Other usual components of dentrifices and mouthwashes may be present e.g. abrasive materials, sudsing agents, binders, humectants, flavouring and sweetening materials, and in the case of toothpaste, a thickening material e.g. water-soluble salts of cellulose ethers, natural gums, colloidal magnesium aluminium silicate or finely divided silica are generally added.
PURPOSE:To easily obtain in high safety the title material extremely mild in digestion and absorption, having taste and mouth feeling similar to those of conventional starch by bringing a fatty acid compound, in the presence of a solvent, into contact with a starch of specified amylose content. CONSTITUTION:(A) 100 pts.wt. of a starch containing 25-60wt.% of amylose is brought, in the presence of (B) pref. 10-100 pts.wt. of a solvent (e.g. water, an alcohol), into contact with (C) pref. 0.5-20 pts.wt. of a fatty acid compound (pref. an amphiphatic substance, esp. fatty acid ester), thus giving the objective material &gt;=10% in the amylose occupancy rate in the component A by the component B.
Processing of the .beta.-amyloid precursor .beta.APP by .beta.- and .gamma.-secetases generates the amyloidogenic peptide A.beta., which has been implicated as a major factor in the etiology of Alzheimer&#39;s disease. The recent identification of BACE as a candidate .beta.-secretase prompted us to investigate the zymogen processing of proBACE and its molecular and cellular trafficking. Our data suggest that furin is the major proprotein convertase responsible for the conversion of proBACE into BACE  within the traps Golgi network. While removal of the 24 as prosegment is required in order for BACE to achieve its maximal catalytic activity in vitro, we provide evidence that proBACE can produce significant quantities of the Swedish mutant .beta.APP sw .beta.-secretase product C99. BACE is palmitoylated at three Cys residues within its transmembrane/cytosolic tail and is sulfated at mature N-glycosylated moieties. Overexpression of full-length BALE in HK293 cells causes a significant increase in the production of C99 and a decrease in the production of the .alpha.-secretase product APPs.alpha.. Although there was little increase in the generation of A.beta.  by full-length BACE, overexpression of either a soluble form of BACE or a form lacking the prosegment lead to a significant increase in A.beta. levels, supporting the hypothesis that mislocalization of BACE can be a major factor in the amyloidogenic processing of .beta.APP.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a hair-treating method by which increasing effect and persistency of the hair are enhanced and texture of cuticle of the hair is controlled and repaired with simplicity and ease.  &lt;P&gt;SOLUTION: Washed hair is dried and a first treating agent containing a protein and a hair-reducing chemical as main ingredients is applied to the hair, and the resultant hair is carded with a comb, etc., to familiarize the hair with the first treating agent. Then, after the nanonized steam is sprayed to the whole hair, a second treating agent containing a protein and a hair-oxidizing chemical as main ingredients is applied to the hair and the hair is carded with a comb, etc., to familiarize the hair with the second treating agent. Then, after the nanonized steam is sprayed to the whole hair, the first treating agent and the second treating agent applied to the hair are rinsed and the hair is dried. A hydrolyzed keratin and/or a hydrolyzed silk protein is used as the protein each contained in the first treating agent and the second agent.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
An electronic document management system includes an acquisition unit, a specifying unit and a database. A medium includes a document image and a plurality of code image two-dimensionally arranged. Each code image includes position information and medium identification information. The acquisition unit acquires a code image corresponding to an operation position on the medium in conjunction with a user&#39;s operation with respect to the medium. The specifying unit specifies the medium identification information included in the code image acquired by the acquisition unit. The database stores personal information associated with the medium identification information specified by the specifying unit.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide resolvin which is a biologically active medicinal agent functional in providing improved understanding of functions of physiological substances and eliminating or diminishing various disease states or conditions.  &lt;P&gt;SOLUTION: A new therapeutic agent generally termed resolvin is isolated. Resolvin is produced from a dietary omega-3 polyunsaturated fatty acid (PUFA) (e.g. eicosapentaenoic acid (EPA) or docosahexaenoic acid (DHA)), cyclooxygenase-II (COX-2) and an analgesic (e.g. aspirin (ASA)). Careful isolation of the compound produced from the combination of the components in an appropriate environment yields a di- and tri-hydroxy EPA or DHA compound having unique structural and physiological properties. An example of the compound is the one represented by the formula.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
Clostridium difficile infections (GDIs) are the number one cause of hospital acquired diarrhea in the United States. Several clinical studies have reported higher incidence and severity of GDI in patients with ulcerative colitis and/or Crohn&#39;s disease. In order to understand the factors underlying increased severity of GDI in IBD patients, we utilized a Dextran Sulfate Sodium (DSS) murine model of inflammatory colitis. In support of clinical observations, our data showed that mice treated with DSS and then infected with C. difficile developed a more severe C. difficile disease compared to untreated mice. Increased severity of disease was measured by increased mortality, weight loss and clinical scores. Importantly, comparison of C. difficile burden between mice with prior DSS colitis and untreated controls showed no differences in C. difficile colonization between the two groups, suggesting that increased severity of disease might be due to the host immune response to infection. Immunophenotyping of immune cells recruted to the colon at the peak of GDI revealed increased levels of CD4+ T cells at the site of infection in mice with prior DSS colitis. Furthermore, depletion of CD4+ T cells using a monoclonal antibody protected mice with prior DSS colitis from severe C. difficile disease. These data have identified a novel role for CD4+ T cells in contributing to increased severity of GDI. Our current studies are aimed at understanding the downstream mechanisms by which these T cells are acting to drive severe disease.
The method of obtaining of N[2-(4-fluorene phenyl 1-methyl]ethyl-Nmethyl-N-propinelamine&#39;s. The invention relates to amines, namely to the proceeding of obtaining N[2-(4-fluorenephenyl 1-methyl]ethyl-N-methyl-N-propinelamine&#39;s or of the admissible salts in pharmacology under the form of racemase or of the optic activ isomer which possess a antidepressing activity that may be used in medicine. The aim of the invention consist of obtaining the new compounds that are more active from this class. The synthesis is performed through reaction p-fluorenephenylacetone with amine, with the formula HNR, R2, where R1, 1H or propynil, R21H or methyl. Ketynine or oximine that are obtained are reduced in the case if R11H, it is propinelat and if R21H, it is methyliat. The final product are obtained under the form of a free base or of a pharmacologic salt admissed as a recemase or a activ optic isomer. The researches show that the new compounds are selected inhibitive very active of monoaminoxidore of B type and absorption inhibitive of tiraamines and biogen amines.
Leukocytes, which may include one or more of monocytes, macrophages, lymphocytes, and neutrophils, are harvested and administered to a region of the body. In the preferred embodiment, leukocytes are harvested from the blood by plasmapherisis, a procedure known to those familiar with blood-banking techniques, and used to treat an intervertebral disc. Plasmapherisis allows the removal of desired blood component(s) from a larger volume of blood than the technique described in the &#39;000 Application. Returning the non-desired blood components to the patient prior to withdraw of additional blood prevents complications that may occur from hypovolemia. Thus, a larger number of leukocytes can be obtained with plasmapherisis than with centrifugation of blood removed during a single blood withdraw. Plasmapherisis can also be used to harvest platelets to treat DDD, HNP and other non-disc-related conditions.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for isolating scFv or intrabody having a defined framework that is stable and soluble in a reducing environment.  &lt;P&gt;SOLUTION: There are provided a method for isolation of CDR in a defined framework that is stable and soluble in a reducing environment as well as scFv obtained thereby. Starting from such scFv with the defined framework, an scFv library can be generated wherein the framework is conserved while at least one complementary determining region (CDR) is randomized. Such library, e.g. in yeast cells, is suitable for screening for antibody/CDR-interactions or for screening for antibodies.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE: An siRNA which suppresses BC200 RNA activation and a pharmaceutical composition containing the same for suppressing tumor metastasis are provided to inhibit cancer cell migration and metastasis and to effectively treat cancer. CONSTITUTION: An siRNA which suppresses BC200 RNA(sequence number 1) activation has a base sequence of 5&#39;-GUAACUUCCCUCAAAGCAA-3&#39;(sequence number 2) or 5&#39;- UUGCUUUGAGGGAAGUUAC-3&#39;(sequence number 3). The siRNA additionally contains a dTdT base sequence at the 3&#39;-end of the siRNA. A vector contains a polynucleotide which enables transcription of shRNA. The vector transcribes shRNA in a cell and the transcribed shRNA is converted into siRNA by cleavage using RNase III. A pharmaceutical composition for suppressing tumor metastasis contains the vector as an active ingredient. The composition additionally contains a pharmaceutically acceptable carrier. [Reference numerals] (AA) Negative control group siRNA
FIELD: medical microbiology.SUBSTANCE: invention relates to medical microbiology and namely to the diagnosis of leptospirosis. As a test strain for detecting antibodies to L. grippotyphosa, a bacterial strain Leptospira interrogans of serogroup Grippotyphosa of serovar grippotyphosa No. 353 &#34;Bank vole 339&#34; isolated from the kidney of the bank vole (Clethrionomis glareolus) is disclosed. The strain was deposited in the Russian collection of reference strains of pathogenic and saprophytic leptospira at the National Research Center for Epidemiology and Microbiology named after academician N.F. Gamalea with number 524. The strain displays pronounced antigenic and immunogenic properties.EFFECT: use of the invention will make it possible to conduct epidemiological investigation of sporadic and group diseases of leptospirosis: serological diagnostics, identification of the source of infection in the focus of the disease as well as monitoring the spread of leptospirosis caused by pathogens of the serogroup Grippotyphosa both among humans and among various animal species.1 cl, 1 tbl, 2 ex
Disclosed is a system (101) and a method (300) for providing mental health or behavioural health services. The system (101) includes a data generation module (210) and a natural language processing module (206), which work together to capture and store user data related to their medical treatment. The data generation module (210) is responsible for storing various types of data pertaining to the user, such as their medical history and treatment information. The natural language processing module (206) captures the user&#39;s responses during treatment and transcribes them into written notes. This allows for easier understanding and sharing of the information within the system (101). The system (101) and the method (300) has potential applications for delivering mental health services through various channels, including interactive computer terminals and mobile applications. This could lead to increased accessibility, convenience, scalability, and potentially improved mental health outcomes for individuals and communities.
PROBLEM TO BE SOLVED: To obtain a cosmetic maintaining a moisture retaining-effect by a humectant, suppressing a greasy feeling in use, having a firm and smooth usability by combining and formulating a humectant with a specific polysaccharide. SOLUTION: This cosmetic is obtained by formulating (A) a fucose-containing polysaccharide with (B) a fumectant. A water-soluble polysaccharide prepared by continuously bonding fucose, galactose and galacturonic acid, having &gt;=100,000 molecular weight is preferable as the component A. The component A has preferably &gt;=20 wt.% of fucose. A polysaccharide having a structure of the formula is especially preferable due to possession of characteristics such as film-forming ability, high viscosity stability of aqueous solution, etc. For example, a polyethylene glycol, hyaluronic acid or the like may be cited as the component B. Preferably the formulated amount of the component A in the total of the cosmetic is 0.01-0.5 wt.% and that of the component B is 0.05-4 wt.%. The cosmetic is preferably in a form of milky lotion or gel.
NEW MATERIAL:Compounds expressed by formula I (n is an integer of 0&lt;=n&lt;=20; R1 and R2 are H, O, halogen, saturated hydrocarbon, etc.: X&lt;-&gt; is monovalent anion). EXAMPLE:Carboxymethylsufonium. USE:Useful as a growth, breeding and oviposition promoter, health improver and vitality enhancer for various animals and a remedy for gastric, duodenal ulcer, gastritis, etc. PREPARATION:A compound expressed by formula II is reacted with a compound expressed by formula III to provide the compounds expressed by formula I. Among the compounds expressed by formula I, a compound in which n is an integer of 1&lt;=n&lt;=5; R1 and R2 are lower alkyl is especially more preferred. The compounds expressed by formula I have sufficient safety even if used as a feed for animals and food or drug for humans unless a large amount thereof is ingested at a time.
PURPOSE: To provide a composition for the treatment or prevention of bacterial plaque, gingival disease and periodontal disease, containing a monoperoxyphthalate compound or its salt or ester and a proper carrier and having an acidic pH range. CONSTITUTION: This composition for oral cavity application contains a compound of the formula I (R&#34; is one or more substituents compatible with a peroxyacid functional group of an aromatic ring) (preferably the compound of the formula II) and a carrier and has a pH of 3.0-5.0. The pH-controlling agent to be used in the composition is e.g. a mono-, di-, tri- or higher polycarboxylate and aminocarboxylate (e.g. citric acid or gluconic acid) and a pyrophosphate. The composition further contains a solvent, a thickener, etc., and, in the case of using as an aqueous toothpaste, it may contain an antioxidation colorant, a flavor, a sweetener, etc. The composition may be used also as a mouth rinsing composition.
Drug delivery devices that are orally administered, and that release active ingredients in the colon, are disclosed. In one embodiment, the active ingredients are those that inactivate antibiotics, such as macrolides, quinolones and beta-lactam containing antibiotics. One example of a suitable active agent is an enzyme such as beta-lactamases. In another embodiment, the active agents are those that specifically treat colonic disorders, such as Chrohn&#39;s Disease, irritable bowel syndrome, ulcerative colitis, colorectal cancer or constipation. The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethyleneimine. The high crosslink density of the polyethyleneimine is believed to stabilize the pectin beads for a sufficient amount of time such that a substantial amount of the active ingredients can be administered directly to the colon.  Advantageously, the amount of polyethyleneimine is sufficient to allow a substantial portion of the pectin beads to pass through the gastrointestinal tract to the colon without releasing the active agent, and is also sufficient such that the pectin beads are sufficiently degraded in the colon to release an effective amount of the active agent.
Nano-particles created using a biodegradable chemical backbone structure suitably designed to permit creation of at least two populations of nano-particles that contain chemical compositions. A first population of particles can contain iodide (I − ) and additional compounds including a pH buffer and iodate (IO 3   − ). A second population of particles can contain compounds that will create a microenvironment of pH of 5&lt;-&lt;7 immediately surrounding the second population particle as it is resides on the surface of mucous membranes and cells found in the sinuses and upper airways or on any mucous membrane. The two particle populations are maintained in a dry state for delivery into the nasal passages. When they become hydrated, they now gain an affinity to each other as an activation event, and particles from the two populations residing in proximity to each other diffuse their chemical components into the microenvironment. The pH within the microenvironment surrounding the particles becomes &lt;7.0 with a preferred value of around 6.4. Iodide and iodate react under the mildly acid microenvironment condition to form molecular iodine, I 2  in situ. The particles in association create I 2  nano-particle factories that persistently generate I 2  over time and thereby sustain an anti-microbial/anti-infective environment within the nasal cavity, sinuses and upper airways or on any other mucus membrane.